US › Healthcare

Treace Medical Concepts Inc (TMCI)

US · Healthcare · Medical Devices

$4.53-0.66%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$45.4M

Revenue YoY

-4.2%

Net profit

$-15.9M

EPS

$-0.24

EPS estimate

$-0.30

Net margin

-35.0%

EPS came in at -0.24 against a street estimate of -0.30 — a beat of 20.0%.

Key statistics

Market cap

$293.3M

Forward P/E

0.0

P/B

4.17

Book value

$1.04

EPS (TTM)

$-0.96

52-week high

$7.61

52-week low

$1.17

50-day MA

$4.47

200-day MA

$2.94

Beta

1.41

Analyst view

Analysts rate Treace Medical Concepts Inc a buy (2 buy, 5 hold, 0 sell out of 7) with an average price target of $5.50.

Shareholding

Insiders

25.27%

Institutions

49.67%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.79%
BlackRock Inc	5.14%
Bank of America Corp	4.94%
Gagnon Securities LLC	4.66%
Gagnon Advisors, LLC	2.36%
Vanguard Capital Management, LLC	2.25%
State Street Corp	1.90%
CIBC Bancorp USA Inc.	1.87%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Treace Medical Concepts Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.